Testagen
KEDG Tetrapeptide | Anterior Pituitary Bioregulator
On this page
What is Testagen?
Testagen (KEDG) is a very short, lab-made tetrapeptide (four amino acids) developed as part of a Russian bioregulator research program, studied for possible effects on pituitary-gland signaling related to thyroid-stimulating hormone. Because thyroid function and testosterone regulation are linked in the physiology literature, researchers also look at whether Testagen has any indirect connection to that pathway — evidence that remains preliminary and mostly non-human. It's sold here strictly as a research chemical for laboratory study, not for use in people or animals.
Key terms:
Testagen is a synthetic tetrapeptide.
Testagen (KEDG, or Lys-Glu-Asp-Gly) is a lab-made peptide of four amino acids. Vladimir Khavinson and his team developed it at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Its sequence comes from extracts of the anterior pituitary gland. Researchers study it for possible effects on the release of TSH (thyroid-stimulating hormone), on thyroid function, and on testosterone regulation further downstream. Like the rest of the Khavinson peptide family, it is proposed to cross cell and nuclear membranes, reach DNA directly, and change gene activity in target tissues.
Key research areas
- Direct systemic absorption
- Precise dosing control
- Bypasses GI degradation
- Supports anterior pituitary function
- Potential thyroid and testosterone optimization through TSH modulation
Researched dosing
This table shows how researchers have structured study dosing schedules for Testagen, including a gradual titration approach used in reported protocols — published research methodology, not personal usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Weeks 1–2 — first step | 100mcg | Once daily | SubQ |
| Weeks 3–4 — second step | 150mcg | Once daily | SubQ |
| Weeks 5–8 — third step | 200mcg | Once daily | SubQ |
| Weeks 9–12 — highest dose studied | 250-300mcg | Once daily | SubQ |
Commonly cycled 12 weeks on, 16+ weeks off.
How it works
At the cell level, Testagen research proposes that this short peptide can enter pituitary cells and interact with gene expression there, potentially influencing how much thyroid-stimulating hormone (TSH) the gland releases.
Testagen (KEDG) is proposed to cross both cell and nuclear membranes to interact directly with DNA in anterior pituitary cells. This may stimulate TSH release, subsequently influencing T3/T4 thyroid hormone production. Improved thyroid function is correlated with normalized testosterone levels, suggesting a potential indirect mechanism for testosterone support.
Molecular data
These figures — molecular weight, four-amino-acid sequence, chain length — are the chemistry fingerprint researchers use to confirm a Testagen sample's identity.
- Weight
- 447.4 Da
- Length
- 4 amino acids
- Type
- Tetrapeptide
H-Lys-Glu-Asp-Gly-OH (KEDG)
Pharmacokinetics
This chart shows how quickly Testagen clears in research studies — a very short timescale that is part of why study protocols favor daily dosing over infrequent large doses.
- Peak
- 0.25 hr
- Half-life
- 0.5 hrs
- Cleared
- ~2.5 hrs
Khavinson et al.
Research applications
This section lists the body systems and research questions scientists have studied for Testagen — largely preclinical pituitary and thyroid-pathway research with very limited human data — a summary of what's been investigated in the literature, not medical claims about people.
Endocrine
Research suggests Testagen may stimulate anterior pituitary function, potentially enhancing release of thyroid-stimulating hormone (TSH) and supporting overall endocrine regulation. Studies indicate Testagen may increase TSH release, subsequently influencing T3 and T4 thyroid hormone production, even without full hypophyseal support. Research correlates hypothyroidism with reduced testosterone; by potentially optimizing thyroid function, Testagen may indirectly support testosterone levels.
Aging
Testagen, as a Khavinson peptide bioregulator, is researched for its potential geroprotective and age-related hormonal support properties.
Metabolic
By influencing thyroid hormone pathways, Testagen may support metabolic rate and metabolic function indirectly.
Dosage reference
- Doses used in research
- 100–300 mcg
- Frequency in studies
- Once daily
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Weeks 4-8 for noticeable hormonal effects
- Storage
- Lyophilized -20°C, Reconstituted 2-8°C
- Cycle length
- 8-12 weeks
- Break between cycles
- 4-6 months between cycles
Interactions
This list shows which other bioregulator-class peptides and thyroid- or hormone-related compounds researchers study alongside Testagen, and flags pairings that call for monitoring.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried Testagen powder into a liquid research solution, including the specific concentration math used in reported protocols.
- Add 3.0mL BAC water to 20mg vial = 6.67mg/mL (6670mcg/mL)
- At this concentration: 1 unit = ~67mcg on U-100 syringe
- Inject BAC water slowly down vial wall, avoid direct contact with powder
- Gently swirl or roll until dissolved - do NOT shake
- Allow to sit 2-3 minutes if any cloudiness, swirl again until clear
- For 100mcg dose: draw 1.5 units; for 200mcg: 3 units; for 300mcg: 4.5 units
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: -20°C, use within As per manufacturer expiry
Reconstituted: 2-8°C, use within Use within recommended period after reconstitution
Open the Testagen reconstitution calculatorQuality indicators
These are the visual and documentation checks researchers use to confirm a Testagen sample is pure and correctly identified — the research base for this compound is limited, so verified sourcing matters even more than usual.
White Lyophilized Powder - Properly freeze-dried Testagen appears as white, fluffy powder cake without clumping or discoloration.
Clear Reconstituted Solution - When mixed with BAC water, solution should be completely clear and colorless with no particles.
Verified Source with COA - Obtain from reputable peptide suppliers with Certificate of Analysis showing purity >98%.
Limited Research Base - Testagen has limited Western clinical data. Most research originates from Russian bioregulator programs.
Discoloration or Particles - Any yellow/brown coloration or visible particles indicates degradation - do not use.
Unknown Source - Never use peptides from unverified sources without third-party testing confirmation.
What to expect
This timeline summarizes what the limited available research literature describes at each stage of a study — research context for comparing studies, not a personal-results promise.
Establishing baseline, minimal noticeable effects
Potential subtle improvements in energy and mood
Possible thyroid function optimization, improved metabolic rate
Full effects on thyroid-testosterone axis may manifest
Safety notes
This section covers handling cautions and regulatory notes for Testagen in a laboratory setting — it flags that no human clinical trials exist and all guidance comes from preclinical research, research-use-only scope, not medical safety advice for people.
- No human clinical trials exist - all guidance from preclinical research
- Contraindicated in individuals with thyroid cancer or hyperthyroidism
- Monitor thyroid function if on thyroid medications
- Start with lower dose to assess individual response
- Rotate injection sites systematically to prevent tissue damage
- Not recommended during pregnancy or breastfeeding
- Consult healthcare provider before use, especially with existing endocrine conditions
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
In hypophysectomized avian models, introduction of the KEDG peptide was associated with changes in thyroid gland morphology, body weight, and follicle structure. Apparent shifts were noted in thyroid-related hormones, suggesting possible interactions with pituitary-thyroid regulation even without hypophyseal support.
Research suggests Testagen stimulates the anterior pituitary gland to increase release of thyroid stimulating hormone (TSH) and subsequently T3 and T4 thyroid hormones. This effect was observed even without hypophyseal support, suggesting direct alteration of protein expression patterns in pituitary tissue.
Clinical study of peptide bioregulators for thyroid correction in elderly residents of Magadan Region. Thyramin (related pituitary bioregulator) demonstrated tissue-specific effects on thyroid cells and restoration of disturbed thyroid tissue function in patients with age-related hypothyroidism.